novo nordisk glp-1 drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings Novo Nordisk's Wegovy pill launch

C., Dampil, O

Growth Opportunity Analysis 2.1.4

The STEP 1, 2 and 3 trials spanned 68 weeks, whereas the STEP 5 trial took place over 104 weeks

declares having received consulting honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk and Bayer and research grants from the British Heart Foundation, the MRC, the National Institute for Health and Care Research, Public Health England, Merck Sharp & Dohme (MSD), Pfizer, Aegerion, Colgate and Roche

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program